Fragile histidine triad protein expression in nonsmall cell lung cancer and correlation with Ki-67 and with p53

European Respiratory Journal

Volumn 21, Issue 5, 2003, Pages 753-758

  Mascaux, C ^a   Martin, B ^a   Verdebout, J M ^a   Meert, A P ^a,b   Ninane, V ^c   Sculier, J P ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b Fonds National Belge de la Recherche Scientifique   (Belgium)

^c SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Fragile histidine triad; Ki 67; Lung neoplasms; Nonsmall cell lung cancer

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; KI 67 ANTIGEN; PROTEIN P53;

ADENOCARCINOMA; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0038732759     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00090202     Document Type: Article

References (36)

1. Sozzi G, Pastorino U, Moiraghi L, et al. Loss of FHIT in lung cancer and preinvasive bronchial lesions. Cancer Res 1998; 58: 5032-5037.
2. Virgilio L, Shuster M, Gollin SM, et al. FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci USA 1996; 93: 9770-9775.
3. Ohta M, Inoue H, Cotticelli MG, et al. The human FHIT gene, spanning the chromosome 3p14.2 fragile site and renal cell carcinoma associated translocation breakpoint, is abnormal in digestive tract cancers. Cell 1996; 84: 587-597.
4. Simon B, Bartsch D, Barth P. Frequent abnormalities of the putative tumour suppressor gene FHIT at 3p14.2 in pancreatic carcinoma cell lines. Cancer Res 1998; 58: 1583-1587.
5. Negrini M, Monaco C, Vorechovsky I, et al. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 1996; 56: 3173-3179.
6. Greenspan DL, Connoly DC, Wu R, et al. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res 1997; 37: 4692-4698.
7. Ozaki K, Enomoto T, Yoshino K, et al. FHIT alterations in endometrial carcinoma and hyperplasia. Int J Cancer 2000; 85: 306-312.
8. Hadaczek P, Kovatich A, Gronwald J, Lubinski J, Huebner K, McCue PA. Loss or reduction of FHIT expression in renal neoplasias: correlation with histogenic class. Hum Pathol 1999; 11: 1276-1283.
9. Baffa R, Gomella LG, Vecchione A, et al. Loss of FHIT expression in transitional cell carcinoma of the urinary bladder. Am J Pathol 2000; 156: 419-424.
10. Yuan BZ, Keck-Waggoner C, Zimonjic DB, Thorgeirsson SS, Popescu NC. Alteration of the FHIT gene in human hepatocellular carcinoma. Cancer Res 2000; 60: 1049-1053.
11. Geradts J, Fong KM, Zimmerman PV, Minna JD. Loss of FHIT expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features. Br J Cancer 2000; 82: 1191-1197.
12. Tseng JE, Kemp BL, Khuri FR, et al. Loss of FHIT is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res 1999; 59: 4798-4803.
13. Otterson GA, Xiao G, Geradts J, et al. Protein expression and functional analysis of the FHIT gene in human tumor cells. J Natl Cancer Inst 1998; 90: 426-432.
14. Siprashvili Z, Sozzi G, Barnes LD, et al. Replacement of FHIT in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 1997; 94: 13771-13776.
15. Druck T, Hadaczek P, Fu TB, et al. Structure and expression of the human FHIT gene in normal and tumour cells. Cancer Res 1997; 57: 504-512.
16. Key G, Becker MH, Baron B, et al. New Ki-67-equivalent murine monoclonal antibodies (MIB1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 1993; 68: 629-636.
17. Martin B, Verdebout JM, Mascaux C, et al. Expression of p53 in preneoplastic and early neoplastic bronchial lesions. Oncology Reports 2002; 9: 223-229.
18. King G, Payne S, Walker F, Murray GI. A highly sensitive detection method for immunohistochemistry using biotinylated thyramme. J Pathol 1997; 183: 237-241.
19. Nishio M, Koshikawa T, Kuroishi T, et al. Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J Clin Oncol 1996; 14: 497-502.
20. Mitsudomi T, Oyama T, Nishida K, et al. P53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival. Ann Oncol 1995; 6: Suppl. 3, 9-13.
21. Demarchi LM, Reis MM, Farhat SA, et al. Prognostic values for stromal proportion and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lung. Mod Pathol 2000; 13: 511-520.
22. Carbognani P, Tincani G, Crafa P, et al. Biological markers in non-small cell lung cancer. Retrospective study of 10 year follow-up after surgery. J Cardiovasc Surg 2002; 43: 545-548.
23. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. World Health Organization. Histological Typing of Lung and Pleural Tumors. International Histological Classification of Tumors. 3rd edn. Heidelberg, Springer, 1999.
24. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-1717.
25. Mehdi SA, Etzell JE, Newman NB, Weidner N, Hohman LJ, Graziano SL. Prognostic significance of Ki-67 immunostaining and symptoms in resected stage I and II non-small cell lung cancer. Lung Cancer 1998; 20: 99-108.
26. Nguyen VN, Mirejovsky P, Mirejovsky T, Melinova L, Mandys V. Expression of cyclin D1, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2. Acta Histochem 2000; 102: 323-338.
27. Seigneurin D, Guillaud P. L'antigène Ki-67, marqueur du cycle cellulaire et de la proliferation tumorale (Ki-67 antigen, a cell cycle and tumour growth marker). Path Biol 1991; 39: 1020-1028.
28. Sozzi G, Tornielli S, Tagliabue E, et al. Absence of FHIT protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res 1997; 57: 5207-5212.
29. Vartanian A, Narovlyansky A, Amchenkova A, Turpaev K, Kisselev L. Interferons induce accumulation of diadenosine triphosphate (Ap3A) in human cultured cells. FEBS Letters 1996; 381: 32-34.
30. Segal E, Le Peeq JB. Relationship between cellular diadenosine 5′,5‴-P1, P4-tetraphosphate level, cell density, cell growth stimulation and toxic stresses. Exp Cell Res 1986; 167: 119-126.
31. Dietrich CU, Pandis N, Teixeira MR, et al. Chromosome abnormalities in benign hyperproliferative disorders of epithelial and stromal breast tissue. Int J Cancer 1995; 60: 49-53.
32. Roz L, Wu CL, Porter S, et al. Allelic imbalance on chromosome 3p in oral dysplastic lesions: an early event in oral carcinogenesis. Cancer Res 1996; 56: 1228-1231.
33. Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 1999; 59: 3333-3339.
34. Sard L, Accornero P, Tornielli S, et al. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci USA 1999; 96: 8489-8492.
35. Roz L, Gramegna M, Ishii H, Croce CM, Sozzi G. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung cancer and cervical cancer cell lines. Proc Natl Acad Sci USA 2002; 99: 3615-3620.
36. Kisselev LL, Justesen J, Wolfson AD, Frolova LY. Diadenosine oligophosphates (Ap(n)A), a novel class of signalling molecules? FEBS Letters 1998; 427: 157-163.